

## **Panacea Biotec receives Rs 1040 Cr for Pentavalent vaccine supply**

10 October 2022 | News

**Easyfive-TT is the world's first fully liquid wP-based Pentavalent vaccine that as launched in India in 2005**

Panacea Biotec has received long-term supply awards worth \$127.30 million (around Rs 1,040 crore) from UNICEF and Pan American Health Organization (PAHO) for supply of its WHO pre-qualified fully liquid Pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib).

UNICEF award is worth \$98.755 million (~Rs 813 crore) for supply of ~99.7 million doses during calendar years 2023-2027 and PAHO award is worth \$28.55 million (~Rs 235 crore) for supply ~24.83 million doses during calendar years 2023-2025.

Paediatric vaccination plays an important role to achieve Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce under-five mortality rate to less than 25 per 1000 live births.

Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Hepatitis B and invasive infections caused by Haemophilus Influenza Type b - becoming the foundation of paediatric immunization programmes across the world.

Easyfive-TT is the world's first fully liquid wP-based Pentavalent vaccine that as launched in India in 2005. After receiving WHO prequalification in 2008, more than 150 million doses have been supplied to over 75 countries globally. EasyFive-TT is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders.